Dubai Investments' MoUs drive regional pharma, glass collaboration at Qatar Industrial Summit
Dubai Investments, a leading diversified investment company, said its subsidiaries, GlobalPharma and Emirates Float Glass (EFG), signed Memorandums of Understanding (MoUs) during the 5 th Higher Committee Meeting of the Integrated Industrial Partnership for Sustainable Economic Development, held in Doha, Qatar.
The agreements, supported by MoIAT (Ministry of Industry and Advanced Technology), align with regional efforts to accelerate industrial growth, enhance economic collaboration, and drive sustainable development across key sectors.
As part of the expanding pharmaceutical collaboration within the region, GlobalPharma, a leading generics partner, signed an MoU with Morocco's Zenith Pharma.
The agreement focuses on technology transfer, licensing, and local manufacturing of critical medications, including injectable biologics, cholesterol treatments, and diabetes solutions.
With an investment exceeding $50 million, the partnership aims to bolster pharmaceutical security and enhance local production capabilities across member countries.
Emirates Float Glass (EFG) signed an MoU to supply high-quality float glass to a regional manufacturing company specializing in glass and silver mirror production.
Under the terms of the MoU, EFG will leverage its advanced production capabilities to ensure a steady and high-quality supply of glass, aligning with broader efforts to enhance regional supply chains and industrial self-sufficiency.
The agreements, signed at the Integrated Industrial Partnership for Sustainable Economic Development attended by industry ministers from the UAE, Egypt, Jordan, Bahrain, Morocco, Qatar, and Turkey, marked a significant milestone, further expanding cross-border cooperation and investment.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Zawya
22-05-2025
- Zawya
Globalpharma inks 4 strategic MoUs during ‘Make it in the Emirates 2025'
'These partnerships are enhancing the country's position as a global hub for high-quality, future-ready healthcare solutions' - Dr. Thani Al Zeyoudi Abu Dhabi, UAE – Globalpharma, the UAE's leading pharmaceutical manufacturer and a wholly owned subsidiary of Dubai Investments PJSC, has signed 4 strategic Memorandums of Understanding (MoUs) during the Make it in the Emirates Forum 2025. The agreements reinforce the UAE's position as a regional hub for pharmaceutical innovation, localization, and advanced healthcare manufacturing. The MoUs were signed individually with each partner, reflecting Globalpharma's tailored approach to strategic collaboration. The agreements were concluded with four international players — PharmaPrimes Laboratories (Jordan), Nerhadou International (Egypt), Aora Health (Spain), and BioSyent Pharma Inc. (Canada). His Excellency Dr. Thani Al Zeyoudi, UAE Minister of State for Foreign Trade and Chairman of the Emirates Drug Establishment witnessed the signing ceremonies with PharmaPrimes Laboratories, Nerhadou International, and Aora Health. These partnerships span critical areas such as technology transfer, product licensing, supply, and local manufacturing. Aligned with the UAE's industrial strategy, the collaborations aim to bolster domestic production, reduce reliance on imports, and accelerate access to next-generation healthcare solutions across the region. 'The strategic collaborations announced by Globalpharma during 'Make it in the Emirates' reflect the UAE's commitment to strengthening domestic pharmaceutical manufacturing and reducing reliance on imports. These partnerships embody the core goals of the 'Make it in the Emirates' initiative—empowering local industry, accelerating innovation, and enhancing the country's position as a global hub for high-quality, future-ready healthcare solutions,' stated His Excellency Dr. Thani Al Zeyoudi, UAE Minister of State for Foreign Trade and Chairman of the Emirates Drug Establishment. "Dubai Investments' long-term strategy is rooted in enabling sectors that drive national progress, and healthcare is central to that vision. These strategic partnerships by Globalpharma reflect the commitment to advancing the UAE's industrial capabilities, promoting knowledge transfer, and building a resilient pharmaceutical ecosystem that supports regional health security and innovation-driven growth," said Mohammed Saeed Al Raqbani, General Manager of Dubai Investments Industries and Masharie and Board Director at Globalpharma. Among the signings, PharmaPrimes Laboratories, a leading CRO based in Amman, Jordan, has signed a strategic partnership with Globalpharma to establish advanced local capabilities for batch release and analysis of biosimilar drugs in the United Arab Emirates. This partnership reflects PharmaPrimes' commitment to strengthening quality infrastructure and providing high-quality, cost-competitive biosimilar therapies across the GCC countries, enhancing the competitiveness of the pharmaceutical sector and improving healthcare quality in the region. In another major agreement, Nerhadou International, one of Egypt's foremost nutraceutical companies, joined forces with Globalpharma to introduce a portfolio of innovative nutraceutical and over the counter (OTC) products tailored to regional health needs. The collaboration is expected to reinforce the UAE's wellness landscape by promoting preventive care and healthier lifestyles. Further expanding its footprint in the wellness space, Globalpharma entered a collaboration with Aora Health, a Spanish company known for its science-driven approach to functional supplements. The partnership will see the co-development and local manufacturing of a premium range of preventive health supplements, enabling quicker market access to European-quality wellness products across the UAE and the MENA region. Rounding out the series of partnerships, Globalpharma signed a Licensing and Supply Agreement with BioSyent Pharma Inc, a specialty pharmaceutical company committed to improving the lives of patients with unique and effective products in Canada and select international markets. The agreement covers the introduction of FeraMAX®, a patented oral iron supplement known for its high bioavailability and reduced gastrointestinal side effects. Globalpharma will undertake secondary packaging and marketing of the product within the UAE. About Globalpharma Globalpharma is a wholly owned subsidiary of Dubai Investments PJSC. Established in 1998, Globalpharma is currently a market leader in key generic pharma segments with a strong regional footprint. Globalpharma started its operations in the UAE in 2003 and expanded its growth in 2008 with product line extensions and new product launches across 14 countries in the GCC and select African markets. Currently Globalpharma has two Manufacturing plants, A state of the art Beta-Lactam Penicillin Manufacturing plant providing the Amoxicillin & AmoxiClav brands in the larger MENA region. Additionally, catering to the Lifestyle disease segments, is a General Medicine Manufacturing Plant with a variety of Liquid & Oral Solid Dose capabilities. About PharmaPrimes Laboratories PharmaPrimes Laboratories is a CRO company offering comprehensive services in drug development and delivery systems, with a strong focus on innovation and delivering effective, high-quality therapeutic solutions in the Middle East and selected global markets. Its services include Research & Development, Pharmaceutical Quality Control, Biosimilar Testing and Analysis, and Bioanalysis and Bioequivalence Studies. PharmaPrimes is committed to the highest standards of quality and international regulations to ensure reliable and efficient service delivery. About Nerhadou International Established in 1996, Nerhadou International is a leading Egyptian pharmaceutical and nutraceutical manufacturer headquartered in 6th of October City, Giza. The company pioneer's innovative healthcare solutions, including oral dispersible film (ODF) technology, and is ranked among Egypt's top 50 pharmaceutical companies for six consecutive years. With a strong presence across the Middle East and Africa, Nerhadou is committed to delivering high-quality, affordable products that enhance health and well-being. About Aora Health Aora Health is a Spain-based nutraceutical company focused on science-backed, condition-specific supplements. With a strong emphasis on research and innovation, Aora delivers high-quality products across key health segments, including digestive, cognitive, and women's health. About BioSyent Pharma Inc BioSyent Pharma Inc is a Canadian specialty pharmaceutical company dedicated to enhancing patient outcomes through innovative, in-licensed healthcare products. With a diverse portfolio spanning therapeutic areas such as iron deficiency, pain management, women's health, and oncology support, BioSyent delivers clinically proven solutions to patients and healthcare professionals across Canada and select international markets. The company is publicly traded on the TSX Venture Exchange under the symbol 'RX'.
Hi Dubai
22-05-2025
- Hi Dubai
Globalpharma Exports to 18 Countries as UAE-Made Medicines Drive Global Expansion
Globalpharma, a subsidiary of Dubai Investments, is ramping up its international footprint with the production of over 120 pharmaceutical products now exported to 18 countries across Africa, the GCC, Eastern Europe, and Asia, according to a senior company official. Mohamad Saeed Al Raqbani, General Manager of Dubai Investments Industries and Board Director at Globalpharma, outlined the company's ambitions to scale globally through advanced pharmaceutical technologies and strategic partnerships. Al Raqbani highlighted Globalpharma's focus on empowering Emirati talent, noting collaborations with both local and international institutions to train professionals in the pharmaceutical sector. He credited the UAE's leadership for investing in human capital, saying this approach is yielding strong local capabilities in key industries. The company's commitment to excellence was underscored by its recent win at the Make it in the Emirates Awards, where it received the Pharmaceutical Quality Award for adhering to top-tier global standards. All of Globalpharma's products are fully manufactured in the UAE, with operations based in Dubai Investments Park. The company is expanding into the development of biological drugs and herbal treatments inspired by Emirati heritage. During the forum, Globalpharma signed four new agreements with partners in Canada, Spain, Egypt, and Jordan. These deals aim to boost the company's global presence and reinforce the UAE's status as a hub for high-quality pharmaceutical production. Al Raqbani reaffirmed Globalpharma's commitment to strengthening the UAE's pharmaceutical security and praised the forum as a vital platform for collaboration, innovation, and industrial growth. News Source: Emirates News Agency
Zawya
20-05-2025
- Zawya
Dubai Investments strengthens industrial leadership at ‘Make it in the Emirates'
Dubai, UAE – Dubai Investments PJSC, the leading diversified investment company listed on the Dubai Financial Market (DFM), is reinforcing its industrial leadership at this year's Make it in the Emirates, showcasing the Group's extensive capabilities across key sectors including glass, aluminium, steel, metal, lighting, polystyrene, and pharmaceuticals. The Group's participation spotlights the contributions of its flagship subsidiaries, including Emirates Glass, Emirates Float Glass, Emirates Building Systems, Emirates Extrusion Factory, White Aluminum Extrusion, Gulf Metal Craft, Emirates Extruded Polystyrene, Lite-tech Industries and Globalpharma—each a leader in its respective field. Collectively, these entities continue to play a pivotal role in driving the UAE's industrial transformation and global trade outreach. During the forum, Globalpharma, a wholly owned subsidiary of Dubai Investments, received Quality Award in SME category (Small and Medium Enterprises), recognising its excellence in implementing quality systems and delivering high-standard, trusted products. In addition, few Dubai Investments subsidiaries signed Memorandums of Understanding (MoUs) with international partners aimed at advancing technology and strengthening the UAE's position as a leading manufacturing hub. Dubai Investments continues to play a key role in exporting UAE-manufactured products to international markets, with its subsidiaries adhering to global quality and sustainability standards. The Group's integrated approach to innovation, localization, and strategic partnerships underlines its long-standing role as one of the pioneers in the UAE's industrial sector. Make It In the Emirates serves as a powerful platform for Dubai Investments to reinforce its legacy of industrial excellence, advance its sustainability commitments, and forge collaborations that shape the future of manufacturing in the UAE and beyond. This year's participation also marks a significant milestone for Dubai Investments as the Group celebrates 30 years of business in the UAE.
